Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease

The Urological Diseases Research Center, Children's Hospital Boston, Boston, MA 02115, USA.
Cancer Research (Impact Factor: 9.28). 07/2009; 69(13):5601-9. DOI: 10.1158/0008-5472.CAN-08-3860
Source: PubMed

ABSTRACT Oncosomes have recently been described as membrane-derived microvesicles secreted by cancer cells, which transfer oncogenic signals and protein complexes across cell boundaries. Here, we show the rapid formation and secretion of oncosomes from DU145 and LNCaP human prostate cancer cells. Oncosome formation was stimulated by epidermal growth factor receptor activation and also by overexpression of membrane-targeted Akt1. Microvesicles shed from prostate cancer cells contained numerous signal transduction proteins and were capable of activating rapid phospho-tyrosine and Akt pathway signaling, and stimulating proliferation and migration, in recipient tumor cells. They also induced a stromal reaction in recipient normal cells. Knockdown of the actin nucleating protein Diaphanous Related Formin 3 (DRF3/Dia2) by RNA interference enhanced rates of oncosome formation, indicating that these structures resemble, and may be identical to, nonapoptotic membrane blebs, a feature of the amoeboid form of cell motility. Analysis of primary and metastatic human prostate tumors using 100K single nucleotide polymorphism arrays revealed a significantly higher frequency of deletion of the locus encoding DRF3 (DIAPH3) in metastatic tumors (P = 0.001) in comparison with organ-confined tumors. Fluorescence in situ hybridization confirmed increased chromosomal loss of DIAPH3 in metastatic tumors in a different cohort of patients (P = 0.006). These data suggest that microvesicles shed from prostate cancer cells can alter the tumor microenvironment in a manner that may promote disease progression. They also show that DRF3 is a physiologically relevant protein that seems to regulate this process.

Download full-text


Available from: Dr. Martin H. Hager, Jul 17, 2015
  • Source
    • "Apoptotic bodies are released during programmed cell death (Hristov et al., 2004), and they carry whole organelles on their inside (Taylor et al., 2008). In addition, some cancer cells release oncosomes, which are vesicles larger than the conventional MVs (Di Vizio et al., 2009; Morello et al., 2013). EVs are formed either at the plasma membrane or in the lumen of various subcellular organelles. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Protozoan parasites and other microorganisms use various pathways to communicate within their own populations and to manipulate their outside environments, with the ultimate goal of balancing the rate of growth and transmission. In higher eukaryotes, including humans, circulating extracellular vesicles are increasingly recognized as key mediators of physiological and pathological processes. Recent evidence suggests that protozoan parasites, including those responsible for major human diseases such as malaria and Chagas disease, use similar machinery. Indeed, intracellular and extracellular protozoan parasites secrete extracellular vesicles to promote growth and induce transmission, to evade the host immune system, and to manipulate the microenvironment. In this review we will discuss the general pathways of extracellular vesicle biogenesis and their functions in protozoan infections.
    Cellular Microbiology 01/2014; 16(3). DOI:10.1111/cmi.12259 · 4.82 Impact Factor
  • Source
    • "Although most mammalian cells secrete extracellular vesicles, their release rates and their molecular components, including proteins, mRNAs, and miRNAs, are dependent on cell type. Furthermore, similar to the cellular proteome, vesicular protein components and their abundance are influenced by cellular status, including stimulation by growth factor (Di Vizio et al., 2009), exposure to the aging process (Lehmann et al., 2008), and transfection with infectious molecules (Coleman et al., 2012). Therefore, quantitation-based comparative proteomic analyses of mammalian extracellular vesicles that are derived from diverse cell types and cellular conditions are expected to provide insights into the emerging biology of extracellular vesicles, to elucidate the biogenesis and pathophysiological functions of extracellular vesicles and to contribute to the discovery of diagnostic and therapeutic target proteins. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Almost all bacteria, archaea, and eukaryotic cells shed extracellular vesicles either constitutively or in a regulated manner. These nanosized membrane vesicles are spherical, bilayered proteolipids that harbor specific subsets of proteins, DNAs, RNAs, and lipids. Recent research has facilitated conceptual advancements in this emerging field that indicate that extracellular vesicles act as intercellular communicasomes by transferring signals to their target cell via surface ligands and delivering receptors and functional molecules. Recent progress in mass spectrometry-based proteomic analyses of mammalian extracellular vesicles derived from diverse cell types and body fluids has resulted in the identification of several thousand vesicular proteins that provide us with essential clues to the molecular mechanisms involved in vesicle cargo sorting and biogenesis. Furthermore, cell-type- or disease-specific vesicular proteins help us to understand the pathophysiological functions of extracellular vesicles and contribute to the discovery of diagnostic and therapeutic target proteins. This review focuses on the high-throughput mass spectrometry-based proteomic analyses of mammalian extracellular vesicles (i.e., exosomes and ectosomes), EVpedia (a free web-based integrated database of high-throughput data for systematic analyses of extracellular vesicles;, and the intravesicular protein-protein interaction network analyses of mammalian extracellular vesicles. The goal of this article is to encourage further studies to construct a comprehensive proteome database for extracellular vesicles that will help us to not only decode the biogenesis and cargo-sorting mechanisms during vesicle formation but also elucidate the pathophysiological roles of these complex extracellular organelles. © 2014 Wiley Periodicals, Inc. Mass Spec Rev.
    Mass Spectrometry Reviews 01/2014; 34(4). DOI:10.1002/mas.21420 · 8.05 Impact Factor
  • Source
    • "esistance to HER-2 inhibitors) Ciravolo et al. (2012) Mutant forms of drug targets (e.g., mutations of EGFR, such as L858R or T790M in circulating EVs may suggest either sensitivity or resistance to EGFR inhibitors, respectively; EV-associated mutant K-ras in colon cancer could be linked to resistance to cetuximab) Linardou et al. (2009), Siena et al. (2009) Target multimerization (e.g., expression patterns of EGFR/HER related receptors in EVs may be suggestive of changing responses to EGFR or HER-2 antagonists) Ritter et al. (2007) Detection of multidrug resistance markers and mediators (e.g., EVs may contain ABC transporters and other mediators of resistance to conventional chemotherapy) "
    [Show abstract] [Hide abstract]
    ABSTRACT: In multicellular organisms both health and disease are defined by patterns of communication between the constituent cells. In addition to networks of soluble mediators, cells are also programed to exchange complex messages pre-assembled as multimolecular cargo of membraneous structures known extracellular vesicles (EV). Several biogenetic pathways produce EVs with different properties, and known as exosomes, ectosomes, and apoptotic bodies. In cancer, EVs carry molecular signatures and effectors of the disease, such as mutant oncoproteins, oncogenic transcripts, microRNA, and DNA sequences. Intercellular trafficking of such EVs (oncosomes) may contribute to horizontal cellular transformation, phenotypic reprograming, and functional re-education of recipient cells, both locally and systemically. The EV-mediated, reciprocal molecular exchange also includes tumor suppressors, phosphoproteins, proteases, growth factors, and bioactive lipids, all of which participate in the functional integration of multiple cells and their collective involvement in tumor angiogenesis, inflammation, immunity, coagulopathy, mobilization of bone marrow-derived effectors, metastasis, drug resistance, or cellular stemness. In cases where the EV role is rate limiting their production and uptake may represent and unexplored anticancer therapy target. Moreover, oncosomes circulating in biofluids of cancer patients offer an unprecedented, remote, and non-invasive access to crucial molecular information about cancer cells, including their driver mutations, classifiers, molecular subtypes, therapeutic targets, and biomarkers of drug resistance. New nanotechnologies are being developed to exploit this unique biomarker platform. Indeed, embracing the notion that human cancers are defined not only by processes occurring within cancer cells, but also between them, and amidst the altered tumor and systemic microenvironment may open new diagnostic and therapeutic opportunities.
    Frontiers in Pharmacology 03/2013; 4:21. DOI:10.3389/fphar.2013.00021
Show more